Brief: Kymera Therapeutics Says KT-621 Well-Tolerated With No Serious Adverse Events Reported

Kymera Therapeutics

08/12/2025 12:41

Dec 8 (Reuters) - Kymera Therapeutics Inc KYMR.O:

KYMERA THERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM BROADEN PHASE 1B CLINICAL TRIAL OF KT-621, A FIRST-IN-CLASS, ORAL STAT6 DEGRADER, IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

KYMERA THERAPEUTICS INC - KT-621 WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS REPORTED

KYMERA THERAPEUTICS INC - KT-621 BROADEN2 PHASE 2B TRIAL TO SEVERE AD ONGOING, DATA EXPECTED BY MID-2027

KYMERA THERAPEUTICS INC - KT-621 ACHIEVES 94% AND 98% STAT6 DEGRADATION IN SKIN AND BLOOD

KYMERA THERAPEUTICS INC - ROBUST CLINICAL ACTIVITY WAS OBSERVED ACROSS ALL DISEASE ENDPOINTS MEASURED FOR KT-621

KYMERA THERAPEUTICS INC - KT-621 SHOWS 63% EASI REDUCTION AND 40% PEAK PRURITUS REDUCTION

Source text: ID:nGNXb912ND

Further company coverage: KYMR.O

 ((Reuters.Briefs@thomsonreuters.com;))